ADB-FUBIATA

Synthetic cannabinoid

ADB-FUBIATA
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

ADB-FUBIATA is a synthetic cannabinoid that has been used in scientific research and is known for its potent agonistic activity at the cannabinoid receptors. It is part of a class of compounds that are often referred to as designer drugs due to their synthetic nature and structural similarity to naturally occurring cannabinoids.

Chemical Structure

ADB-FUBIATA is chemically classified as an indazole-based synthetic cannabinoid. Its structure includes a 1-(4-fluorobutyl) group attached to an indazole core, with a carbonyl group linked to a tert-leucine moiety. This configuration is responsible for its high affinity and activity at the cannabinoid receptors.

Pharmacology

Synthetic cannabinoids like ADB-FUBIATA act primarily as agonists at the CB1 and CB2 receptors, which are part of the endocannabinoid system. These receptors are involved in a variety of physiological processes including pain sensation, mood regulation, and appetite control. ADB-FUBIATA's interaction with these receptors can lead to effects similar to those of tetrahydrocannabinol (THC), the active component of cannabis.

Legal Status

The legal status of ADB-FUBIATA varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of medical use. It is often included in legislation targeting synthetic cannabinoids and other novel psychoactive substances.

Health Effects

The use of synthetic cannabinoids like ADB-FUBIATA can lead to a range of adverse health effects. These may include tachycardia, hypertension, nausea, vomiting, and anxiety. In severe cases, it can cause psychosis, seizures, and renal failure. The variability in potency and purity of these substances increases the risk of overdose and other harmful effects.

Synthesis

The synthesis of ADB-FUBIATA involves the reaction of 1-(4-fluorobutyl)-1H-indazole-3-carboxylic acid with tert-leucine in the presence of a coupling agent. This process requires careful control of reaction conditions to ensure the desired product is obtained with high purity.

Related pages

• Synthetic cannabinoids
• Cannabinoid receptor
• Designer drug
• Endocannabinoid system